BIORCHESTRA
BIORCHESTRA is dedicated to developing innovative medicines to improve patients' lives, focusing on transformational RNA medicines and delivery systems for neurodegenerative and rare CNS diseases. They aim to solve major unmet medical needs through their pioneering research and technology platform.
Industries
Nr. of Employees
medium (51-250)
BIORCHESTRA
Products
Lead RNA therapeutic program (BMD-001)
Lead RNA therapeutic program focused on neurodegenerative disease indications, including Parkinson's disease; progressed through preclinical development and presented data at scientific meetings.
Targeting technology platform for CNS delivery (BDDS-style platform)
A platform designed to enable targeted delivery of nucleic acid therapeutics to the brain/central nervous system for improved tissue targeting.
Lead RNA therapeutic program (BMD-001)
Lead RNA therapeutic program focused on neurodegenerative disease indications, including Parkinson's disease; progressed through preclinical development and presented data at scientific meetings.
Targeting technology platform for CNS delivery (BDDS-style platform)
A platform designed to enable targeted delivery of nucleic acid therapeutics to the brain/central nervous system for improved tissue targeting.
Services
Collaborative research and licensing
Research partnerships and option/licensing agreements to apply targeting and delivery technologies in joint programs.
Collaborative research and licensing
Research partnerships and option/licensing agreements to apply targeting and delivery technologies in joint programs.
Expertise Areas
- RNA therapeutics development
- CNS-targeted drug development
- Target discovery and translational research
- Nanomedicine and polymer formulation
Key Technologies
- RNA therapeutics
- siRNA
- CNS-targeted delivery platforms
- Nanoparticle/nanomedicine delivery